MAP2K1 and infection: Instead, groups of mice treated with the MEK1/2 inhibitor had reduced body mass loss as a marker of illness with decreased neutrophil mediated inflammation compared to vehicle treated groups, and PD0325901 treated mice did not exhibit a loss of body mass or illness over a six day monitoring period, suggesting there was no resurgent infection.